Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide

  • Palomo, Marta|||0000-0002-3261-6577
  • Vera, Manuel|||0000-0001-9937-7235
  • Martín, Susana
  • Torramadé-Moix, S.
  • Martínez Sánchez, Julia
  • Belen Moreno, A.
  • Carreras, Enric|||0000-0002-3134-9964
  • Escolar, Ginès
  • Cases Amenós, Aleix|||0000-0002-6962-8184
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Endothelial dysfunction is an earlier contributor to the development of atherosclerosis in chronic kidney disease (CKD), in which the role of epigenetic triggers cannot be ruled out. Endothelial protective strategies, such as defibrotide (DF), may be useful in this scenario. We evaluated changes induced by CKD on endothelial cell proteome and explored the effect of DF and the mechanisms involved. Human umbilical cord vein endothelial cells were exposed to sera from healthy donors (n = 20) and patients with end-stage renal disease on haemodialysis (n = 20). Differential protein expression was investigated by using a proteomic approach, Western blot and immunofluorescence. HDAC1 and HDAC2 overexpression was detected. Increased HDAC1 expression occurred at both cytoplasm and nucleus. These effects were dose-dependently inhibited by DF. Both the HDACs inhibitor trichostatin A and DF prevented the up-regulation of the endothelial dysfunction markers induced by the uraemic milieu: intercellular adhesion molecule-1, surface Toll-like receptor-4, von Willebrand Factor and reactive oxygen species. Moreover, DF down-regulated HDACs expression through the PI3/AKT signalling pathway. HDACs appear as key modulators of the CKD-induced endothelial dysfunction as specific blockade by trichostatin A or by DF prevents endothelial dysfunction responses to the CKD insult. Moreover, DF exerts its endothelial protective effect by inhibiting HDAC up-regulation likely through PI3K/AKT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Endothelial damage, inflammation and immunity in chronic kidney disease

  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Torramade-Moix, S.
  • Pascual, G.
  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Martínez Sánchez, Julia
  • Vera, M.
  • Cases Amenós, Aleix|||0000-0002-6962-8184
  • Escolar, Ginès
Chronic kidney disease (CKD) patients have an accelerated atherosclerosis, increased risk of thrombotic-ischemic complications, and excessive mortality rates when compared with the general population. There is also evidence of an endothelial damage in which the proinflammatory state, the enhanced oxidative stress, or the accumulation of toxins due to their reduced renal clearance in uremia play a role. Further, there is evidence that uremic endothelial cells are both involved in and victims of the activation of the innate immunity. Uremic endothelial cells produce danger associated molecular patterns (DAMPS), which by binding to specific pattern recognition receptors expressed in multiple cells, including endothelial cells, induce the expression of adhesion molecules, the production of proinflammatory cytokines and an enhanced production of reactive oxygen species in endothelial cells, which constitute a link between immunity and inflammation. The connection between endothelial damage, inflammation and defective immunity in uremia will be reviewed here.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid, experimental studies in thromboelastometry

  • Koller, Tobias|||0000-0002-6247-0193
  • Kinast, Nadia
  • Guilarte Castellanos, Andres
  • Pérez García, Sergio|||0000-0003-4242-0858
  • Paniagua, Pilar|||0000-0002-0215-1561
  • Vintro, Xavi León|||0000-0002-9673-5786
  • Arranz, Jose Mateo
  • Vilalta, Noelia|||0000-0002-3961-3563
  • García, Ma. Victòria Moral
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Aznar-Salatti, Jose
  • Albaladejo, Gines Escolar
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Colloid fluids supplemented with adequate combinations of coagulation factor concentrates with the capability to restore coagulation could be a desirable future treatment component in massive transfusion. Starting from a coagulation factor and blood cell-free albumin solution we added Prothrombin Complex Concentrate, Fibrinogen Concentrate and Factor XIII in different combinations and concentrations to analyze their properties to restore thromboelastometry parameters without the use of plasma. Further analysis under the presence of platelets was performed for comparability to whole blood conditions. Albumin solutions enriched with Fibrinogen Concentrate, Factor XIII and Prothrombin Complex Concentrate at optimized concentrations show restoring coagulation potential. Prothrombin Complex Concentrate showed sufficient thrombin formation for inducing fibrinogen polymerization. The combination of Prothrombin Complex Concentrate and Fibrinogen Concentrate led to the formation of a stable in vitro fibrin clot. Fibrinogen and Factor XIII showed excellent capacity to improve fibrin clot firmness expressed as Amplitude at 10 min and Maximal Clot Firmness. Fibrinogen alone, or in combination with Factor XIII, was able to restore normal Amplitude at 10 min and Maximal Clot Firmness values. In the presence of platelets, the thromboelastometry surrogate parameter for thrombin generation (Clotting Time) improves and normalizes when compared to whole blood. Combinations of coagulation factor concentrates suspended in albumin solutions can restore thromboelastometry parameters in the absence of plasma. This kind of artificial colloid fluids with coagulation-restoring characteristics might offer new treatment alternatives for massive transfusion. Study registered at the institutional ethic committee "Institut de Recerca, Hospital Santa Creu i Sant Pau, with protocol number IIBSP-CFC-2013-165.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Thrombotic microangiopathies assessment, mind the complement

  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Guillén-Olmos, Elena
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Garcia-Herrera, Adriana
  • Piñeiro, Gastón Julio|||0000-0003-3806-4731
  • Poch, Esteban|||0000-0002-6492-024X
  • Carreras, Enric|||0000-0002-3134-9964
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Palomo, Marta|||0000-0002-3261-6577
When faced withmicroangiopathic haemolytic anaemia, thrombocytopenia and organ dysfunction, clinicians should suspect thromboticmicroangiopathy (TMA). The endothelial damage that leads to this histological lesion can be triggered by several conditions or diseases, hindering an early diagnosis and aetiological treatment. However, due to systemic involvement in TMA and its lowincidence, an accurate early diagnosis is often troublesome. In the last few decades,major improvements have beenmade in the pathophysiological knowledge of TMAs such as thrombotic thrombocytopenic purpura [TTP, caused by ADAMTS-13 (a disintegrin andmetalloproteinase with a thrombospondin Type 1motif,member 13) deficiency] and atypical haemolytic uraemic syndrome (aHUS, associated with dysregulation of the alternative complement pathway), together with enhancements in patientmanagement due to newdiagnostic tools and treatments. However, diagnosis of aHUS requires the exclusion of all the other entities that can cause TMA, delaying the introduction of terminal complement blockers, which have shown high efficacy in haemolysis control and especially in avoiding organ damage if used early. Importantly, there is increasing evidence that other forms of TMA could present overactivation of the complement system, worsening their clinical progression. This review addresses the diagnostic and therapeutic approach when there is clinical suspicion of TMA, emphasizing complement evaluation as a potential tool for the inclusive diagnosis of aHUS, as well as for the improvement of current knowledge of its pathophysiological involvement in other TMAs. The development of both new complement activation biomarkers and inhibitory treatments will probably improve themanagement of TMA patients in the near future, reducing response times and improving patient outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens

  • Martínez Sánchez, Julia
  • Castrillo, Leticia
  • Jerez, Didac
  • Torramade-Moix, Sergi|||0000-0003-4409-9607
  • Palomo, Marta|||0000-0002-3261-6577
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Zafar, M. Urooj
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Sánchez, Pablo|||0000-0003-2787-822X
  • Badimon, Juan Jose
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Escolar, Ginès
  • Roqué, Mercè
We evaluated modifications in the hemostatic balance of different concentrations of apixaban (APIX) in 25 healthy donors and 53 patients treated with aspirin (ASA, n = 21), ASA and clopidogrel (ASA + CLOPI, n = 11), or ASA and ticagrelor (ASA + TICA, n = 21). Blood samples from participants were spiked ex vivo with apixaban 0 (APIX0), 40 (APIX40), and 160 ng/mL (APIX160). We assessed the effects of APIX on (1) clot formation, by ROTEM thromboelastometry; (2) thrombin generation primed by platelets; and (3) platelet and fibrin interactions with a thrombogenic surface, in a microfluidic model with circulating blood. APIX caused dose-related prolongations of clotting time with minimal impact on other ROTEM parameters. Thrombin generation was significantly inhibited by APIX160, with ASA + TICA actions showing the strongest inhibition (p < 0.01 vs APIX0). Microfluidic studies showed that APIX160 was more potent at suppressing platelet and fibrin interactions (p < 0.001 vs. APIX0). APIX40 demonstrated a consistent antithrombotic action but with a favorable protective effect on the structural quality of fibrin. APIX potentiated the antithrombotic effects of current antiplatelet regimens. APIX at 40 ng/mL, enhanced the antithrombotic action of single or dual antiplatelet regimens but was more conservative for hemostasis than the 160 ng/mL concentration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

T-TAs® 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion

  • Sanz, Cristina
  • Escolar, Ginès
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Samanbar, Sahar
  • Piñeyroa, Juan A.
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Pino, Marc
  • Torramadé-Moix, Sergi
  • Martínez Sánchez, Julia
  • Lozano, Miquel|||0000-0003-2593-833X
background - Current laboratory tests fail to evaluate the hemostatic function of platelets in patients with thrombocytopenia. We investigated the use of the Total Thrombus-Formation Analysis System (T-TAS® 01 [Fujimori Kogyo Co, Tokyo, Japan]) to evaluate hemostasis under conditions of experimental thrombocytopenia, and in patients before and after platelet transfusion. materials and methods - Specific T-TAS 01 chips, for thrombocytopenic conditions, were used. The area under the curve (AUC) and occlusion time (OT, min) were measured in: (i) experimentally induced thrombocytopenia (183±15 to 6.3±1.2×10 platelets/µL) in blood samples from healthy donors (No.=13), and (ii) blood from oncohematological thrombocytopenic patients (No.=48), before and after platelet transfusion. The influences of hematocrit and number of transfusions were analyzed in these patients. results - Progressive reductions of AUC and prolongations of OT related significantly to decreasing platelet counts (p<0.05 for all) in experimental thrombocytopenia. In samples from thrombocytopenic patients, platelet counts, AUC and OT were, respectively, 10.8±0.6×10/µL, 175.2±59, and 27.2±1 min before transfusion; and 22±1.5×10/µL, 400.8±83 and 22.9±1.5 min after platelet transfusion (p<0.01 for all). A hematocrit below 25% or exposure to ten or more previous platelet transfusions had a negative impact on the T-TAS 01 performance in patients. In vitro correction of the hematocrit improved the hemostatic response in thrombocytopenic patients. discussion - T-TAS 01 measurements were sensitive to low platelet counts in the experimental setting. The technology was sensitive to evaluate the hemostatic capacity of platelet transfusions. Exposure to multiple medications, repeated platelet transfusions and lower hematocrits may interfere with the hemostatic performance in oncohematological patients with thrombocytopenia.